In accordance with the final results of the Phase III ADMIRAL study, single-agent gilteritinib significantly improved survival and complete response (CR)/CR with incomplete platelet recovery (CRP) rates in FLT3-mutated AML patients compared to salvage chemotherapy [median OS: 9.3 months (gilteritinib) versus 5.6 months (chemotherapy), CR/CRP: 34% (gilteritinib) versus 15% (chemotherapy)] (Perl et al., 2019). Here, FLT3 is linked to acute myeloid leukemia.